SAN FRANCISCO--(BUSINESS WIRE)--Medical professionals seeking to treat the serious and growing problem of hospital-acquired gram-negative pneumonia may have a new weapon: NKTR-061 (inhaled-amikacin), which is a product candidate being developed by Nektar Therapeutics (Nasdaq:NKTR).
Results of a Phase 2a clinical trial evaluating the use of NKTR-061 (Inhaled Amikacin) to treat mechanically ventilated patients with hospital-acquired gram-negative pneumonia were presented today during a poster session from 11:15 a.m. – 2:00 p.m. Eastern Time (8:15 a.m. – 11:00 a.m. Pacific Time) at the annual American Thoracic Society (ATS) International Conference at the San Francisco Marriott Hotel. Electronic copies of the posters presented are available on the Investor Relations section of
